Moticlod (Clodronate Disodium Tetrahydrate)

Clodronate Disodium Tetrahydrate, the active ingredient in Moticlod, is a bisphosphonate presented as a sterile injectable solution for intramuscular and intravenous use. It is employed to treat conditions characterized by excessive bone resorption, such as osteoporosis, Paget's disease of bone, and hypercalcemia associated with malignancy.

GNH USA supplies Moticlod as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics across global markets worldwide. The company emphasizes quality assurance, regulatory compliance and reliable logistics to meet international standards.

Moticlod, a bisphosphonate that inhibits bone resorption, is indicated for several bone‑related conditions.

- Osteoporosis: reduces bone loss and fracture risk in postmenopausal women and men with primary osteoporosis. - Paget's disease of bone: normalizes abnormal bone remodeling and alleviates bone pain. - Hypercalcemia of malignancy: lowers elevated serum calcium levels associated with cancer‑related bone turnover.

Clodronate may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Flu‑like symptoms: transient fever, chills, muscle aches. - Gastrointestinal discomfort: nausea, abdominal pain or dyspepsia. - Injection site reactions: pain, erythema or swelling at the administration site. - Transient elevation of liver enzymes.

Serious or Rare Side Effects: - Acute renal failure: sudden loss of kidney function, especially in patients with pre‑existing renal impairment. - Severe hypocalcemia: markedly low serum calcium that may cause tetany or cardiac arrhythmias. - Osteonecrosis of the jaw: rare bone necrosis associated with invasive dental procedures.

Prior to initiating clodronate therapy, several safety considerations should be evaluated.

- Renal function: assess baseline kidney function and monitor during treatment. - Calcium levels: correct hypocalcemia before starting therapy and maintain adequate calcium intake. - Concomitant bisphosphonates: avoid using other bisphosphonates concurrently to prevent excessive bone turnover suppression. - Pregnancy and lactation: use only if clearly indicated, as safety data are limited. - Elderly patients: monitor for dehydration and renal impairment, adjusting dose as needed. - Store at ambient temperature: keep in the original container, protect from light and moisture.

Clodronate can interact with other medicines, influencing safety or effectiveness.

Major Interactions (Avoid): - Aminoglycoside antibiotics: increased risk of nephrotoxicity when combined. - Loop diuretics: may exacerbate hypocalcemia and renal stress. - Concurrent use with other bisphosphonates: risk of over‑suppression of bone remodeling.

Moderate Interactions (Monitor Closely): - Calcium or vitamin D supplements: may reduce clodronate absorption if taken simultaneously; separate dosing times. - Non‑steroidal anti‑inflammatory drugs (NSAIDs): can heighten risk of renal impairment. - Antacids containing aluminum or magnesium: may interfere with drug bioavailability; timing adjustment recommended.